Lv1
30 积分 2025-03-20 加入
A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer
2个月前
已完结
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
2个月前
已完结
Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis
2个月前
已完结
In Search of the Long-Desired ‘Copernican Therapeutic Revolution’ in Small-Cell Lung Cancer
2个月前
已完结
A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)—design and rationale
3个月前
已完结
Durvalumab for the treatment of non-small cell lung cancer
4个月前
已完结
Splicing factor USP39 promotes ovarian cancer malignancy through maintaining efficient splicing of oncogenic HMGA2
4个月前
已完结
Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma
5个月前
已完结
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
5个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
5个月前
已关闭
皖公网安备34019202002308
